Pricing Log in Create free account
Saturday 17 October 2026 Export EOCN’s income statement to Excel — free account

Eocene Ltd.

EOCN Healthcare Biotechnology

In the quarter to June 2026, EPS grew 43.3% and free cash flow fell 67.7%, each against the same quarter a year earlier.

2.85 0.20 −6.56%
Market cap
$3.2M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
4/9
Altman Z
26.94
Beneish M
−1.67
Dividend safety
n/a
Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3.18
Revenue 2.04
Net Income (11.34)
Free Cash Flow (8.54)
Net Debt (8.92)
Current Ratio 4.16 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (4.49) (negative: loss-making)
P/S ratio 1.33
P/B ratio 0.21
Past 5Y EPS Growth —
This Y EPS Growth 40.32% (at or above 15%: strong)
Next Y EPS Growth 80.98% (at or above 15%: strong)
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth 52.34% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −3.0×, against a ten-year median of 2.5×; over the ten years it ranged from −7.8× in 2022 to 144× in 2018.
P/S against its own 10 years 17.46%
10-year low 10-year high
P/B against its own 10 years 17.55%
10-year low 10-year high
EV/FCF against its own 10 years 44.98%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 11 12 11 9
Receivables 0 1 0 0
Inventory — — — —
Other 2 3 7 2
13 16 19 12
2023 2024 2025 Q'26
Payables 2 1 2 2
ST’ Debt — — — —
Other — — — —
3 2 3 3

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (3.06%) (18.60%) 5.54%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’18 0 0 2 0 2
’17 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (2) — — —
’25 (1) (1) (2) (2) (6)
’24 (2) (1) (1) (2) (6)
’23 (2) (1) (2) (1) (6)
’22 (5) (6) (3) (4) (19)
’21 (9) (8) (9) (7) (33)
’20 (7) (6) (6) (8) (26)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (2) — — —
’25 (1) (1) (2) (2) (6)
’24 (2) (1) (1) (2) (6)
’23 (2) (1) (2) (1) (6)
’22 (5) (6) (3) (4) (19)
’21 (9) (8) (9) (7) (33)
’20 (7) (6) (6) (8) (26)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.32) (2.86) — — —
’25 (4.96) (5.04) (2.64) (7.36) (19.12)
’24 (16.78) (13.20) (18.48) (16.16) (64.64)
’23 (104.68) (91.24) (23.05) (94.12) (240.10)
’22 (345.57) (215.98) (302.37) (143.99) (1.02k)
’21 (547.14) (475.15) (446.35) (431.96) (1.90k)
’20 (417.56) (374.36) (460.75) (691.13) (1.94k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4,003.20 4,939.20 5,198.40 4,921.92 4,262.40 2,476.80 417.60 24.96 20.48 5.85

Analyst estimates 2026–2028

Powerpack
High 11,397.60 14,083.20 38,966.40 13,492.80 10,353.60 9,000.00 3,139.20 1,360.80 190.40 28.88
People
People Employees 16 17 21 21 24 24 10 8 6 9
Revenue/emp, $m 0.03 0.06 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income, $m
Income, $m Revenue 0 1 2 — — — — — — —
Gross margin, % 100.00 100.00 100.00 0.00 0.00 0.00 0.00 — — —
EBT (17) (12) (10) (20) (29) (32) (18) (7) (8) (10)
EBT margin, % (3,607.49) (1,133.55) (479.93) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (17) (12) (10) (20) (29) (32) (18) (7) (8) (10)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 59.11 124.71 161.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings (2,145.39) (1,411.06) (777.52) (1,396.66) (1,943.81) (1,900.61) (1,022.30) (240.10) (64.64) (19.12)
Cash flow (1,535.32) (1,387.01) (716.11) (1,016.12) (1,776.15) (1,923.51) (1,057.20) (213.09) (50.52) (11.72)
Capex (0.51) (1.38) (7.14) (0.82) (2.97) (0.64) (0.23) 0.00 0.00 0.00
Free cash flow (1,535.82) (1,388.39) (723.25) (1,016.94) (1,779.12) (1,924.15) (1,057.43) (213.09) (50.52) (11.72)
Book value 1,401.90 1,815.52 6,975.71 4,751.90 2,983.31 1,783.45 767.03 481.91 140.27 29.29
Shares, m 0 0 0 0 0 0 0 0 0 1
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 — — — — — — —
P/S 0.00 108.42 60.81 — — — — — — —
P/B 3.73 7.45 1.41 — — — — — — —
EV/Sales 0.00 90.91 19.53 — — — — — — —
EV/FCF (2.13) (8.17) (4.37) — — — — — — —
Cash, $m
Cash, $m Operating cash flow (12) (12) (9) (15) (26) (33) (19) (6) (6) (6)
Capex 0 0 0 0 0 0 0 — — —
Free cash flow (12) (12) (9) (15) (26) (33) (19) (6) (6) (6)
Balance, $m
Balance, $m Working capital 11 15 88 69 44 30 12 10 14 16
Total debt — — — 0 0 0 0 — — —
Net debt (15) (19) (84) (47) (47) (35) (14) (11) (12) (11)
Shareholders’ equity 11 16 88 70 44 30 13 14 16 16
Returns, %
Returns, % ROA (83.28) (68.15) (17.88) (24.40) (44.43) (72.97) (67.21) (41.65) (42.80) (55.53)
ROIC 0.00 0.00 (177.49) (62.05) 0.00 0.00 0.00 (138.82) (89.77) (114.43)
ROE (103.94) (91.54) (19.01) (25.94) (50.47) (86.98) (81.36) (50.63) (49.77) (64.21)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2018 · latest quarter Dec 2018

Charts ten years each

Eocene Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PBLA Panbela Therapeutics Inc. $3.4M — (loss-making) — — n/m +66.23% (above 0%: growing) — 0.00% Compare
CMND Clearmind Medicine Inc. $3.3M — (loss-making) — — n/m −77.94% (below 0%: shrinking) 0.00% 0.00% Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR $3.2M — (loss-making) — (loss-making) −100.78% (below 0%: shrinking) n/m −2.73% (below 0%: shrinking) 100.00% 0.00% Compare
CLDI Calidi Biotherapeutics, Inc. $3.2M — (loss-making) — — n/m +11.16% (above 0%: growing) — 0.00% Compare
EOCN Eocene Ltd. $3.2M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −67.74% (below 0%: shrinking) 0.00% 0.00%
SXTP 60 Degrees Pharmaceuticals Inc. $3.2M — (loss-making) — (loss-making) −32.48% (below 0%: shrinking) n/m −54.33% (below 0%: shrinking) 27.32% (1,092.40%) Compare
APVO Aptevo Therapeutics Inc. $3.1M 0.0× — (loss-making) +28.62% (above 0%: growing) n/m +23.11% (above 0%: growing) 0.00% 0.00% Compare
GRI GRI Bio, Inc. $3.1M 0.0× — (loss-making) — n/m +54.33% (above 0%: growing) 0.00% 0.00% Compare
REVB Revelation Biosciences, Inc. $3.0M — (loss-making) — — n/m −35.29% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $3.2M — — −32.48% — +4.22% 0.00% 0.00%

All 614 Biotechnology stocks →

Eocene Ltd. (EOCN) key facts

  • Eocene Ltd. (EOCN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, EOCN traded at $2.85, a market capitalization of $3.2 million.
  • Return on equity was −64.2% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

Eocene Ltd. (EOCN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/EOCN · Data as of Dec 31, 2018 · For information only; not investment advice. · © 2026 stockrow.com